Rakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...

Pre-clinical studies show potential synergy in treatment of solid tumors by combining a PARP inhibitor with inhibition of HDAC enzymes.

The funds will be used to support Skylight on its pathway to profitability.

Skylight Health continues to see opportunities to expand value-based contracting efforts beyond traditional Medicare and Medicare Advantage.

The Company is finalizing the Phase 3 study protocol of apabetalone in PCC and plans to launch the trial in the first half of 2023..

Skylight Health continues to see opportunities to expand current and engage with new provider partners for MA value-based care...

Research revenue in 2022 has more than doubled the $300,000 earned in 2021. The team continues to plan for further expansion to new markets.